Trial Profile
A Randomized, Pilot, Open-Label, Monocenter, Efficacy and Safety Study Examining the Effects of Peginterferon Alfa-2a (Pegasys) With or Without Ribavirin (Copegus) in Patients With Chronic Hepatitis D
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jul 2016
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis D
- Focus Therapeutic Use
- Sponsors Roche
- 11 Apr 2016 New trial record